Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia
Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.
Sparsentan | 24/10/2025 | By Dineshwori | 304
Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan
In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
Sparsentan | 01/02/2025 | By Abha | 529
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy